



JOSHI VISHAL & ASSOCIATES
CHARTERED ACCOUNTANTS

2851, Top Floor,
Sector 22-C, Chandigarh-160 022
Tel. : 0172-5076322, 5088322
Fax : 0172-4676322 Mob. : 098152 27840
e-mail : joshivishal72@rediffmail.com

Independent Auditor's Report

To the Members of
Biodeal Pharmaceuticals Private Limited

Report on the Financial Statements

We have audited the accompanying financial statements of **Biodeal Pharmaceuticals Private Limited ("the Company")** which comprise the Balance Sheet as at March 31, 2017, the Statement of Profit and Loss, Cash Flow Statement for the year then ended, and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit.

We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made there under.

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.



An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the Company has in place an adequate internal financial controls system over financial reporting and the operating effectiveness of such controls. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2017, and its Profit/Loss and its Cash Flow for the year ended on that date.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2016 ("the Order"), as amended, issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by section 143 (3) of the Act, we report that:
 - a. we have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
 - b. in our opinion proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
 - c. the Balance Sheet, the Statement of Profit and Loss and the Cash Flow Statement dealt with by this Report are in agreement with the books of account
 - d. in our opinion, the aforesaid financial statements comply with the Accounting Standards specified under section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.



- e. On the basis of written representations received from the directors as on March 31, 2017 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2017 from being appointed as a director in terms of Section 164 (2) of the Act.
- f. With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report.
- g. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- i. The Company does not have any pending litigations which would impact its financial position.
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
 - iv. The Company has provided requisite disclosures in its standalone Ind AS financial statements as to holdings as well as dealings in Specified Bank Notes during the period from 8 November, 2016 to 30 December, 2016 and these are in accordance with the books of accounts maintained by the Company.

PLACE: CHANDIGARH

DATE: 21-02-2017

For **JOSHI VISHAL & ASSOCIATES**
CHARTERED ACCOUNTANTS



(VISHAL JOSHI)
M.NO. 097336
FRN :016437N

"Annexure A" to the Independent Auditors' Report

Referred to in paragraph 1 under the heading 'Report on Other Legal & Regulatory Requirement' of our report of even date to the financial statements of the Company for the year ended March 31, 2017:

- 1) (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets;
- (b) The Fixed Assets have been physically verified by the management in a phased manner, designed to cover all the items over a period of three years, which in our opinion, is reasonable having regard to the size of the company and nature of its business. Pursuant to the program, a portion of the fixed asset has been physically verified by the management during the year and no material discrepancies between the books records and the physical fixed assets have been noticed.
- (c) The title deeds of immovable properties are held in the name of the company.
- 2) (a) The management has conducted the physical verification of inventory at reasonable intervals.
- b) The discrepancies noticed on physical verification of the inventory as compared to books records which has been properly dealt with in the books of account were not material.
- 3) The Company has not granted any loans, secured or unsecured to companies, firms, Limited Liability partnerships or other parties covered in the Register maintained under section 189 of the Act. Accordingly, the provisions of clause 3 (iii) (a) to (c) of the Order are not applicable to the Company and hence not commented upon.
- 4) In our opinion and according to the information and explanations given to us, the company has complied with the provisions of section 185 and 186 of the Companies Act, 2013 In respect of loans, investments, guarantees, and security.
- 5) The Company has not accepted any deposits from the public and hence the directives issued by the Reserve Bank of India and the provisions of Sections 73 to 76 or any other relevant provisions of the Act and the Companies (Acceptance of Deposit) Rules, 2015 with regard to the deposits accepted from the public are not applicable.
- 6) As informed to us, the maintenance of Cost Records has not been specified by the Central Government under sub-section (1) of Section 148 of the Act, in respect of the activities carried on by the company.



- 7) (a) According to information and explanations given to us and on the basis of our examination of the books of account, and records, the Company has been generally regular in depositing undisputed statutory dues including Provident Fund, Employees State Insurance, Income-Tax, Sales tax, Service Tax, Duty of Customs, Duty of Excise, Value added Tax, Cess and any other statutory dues with the appropriate authorities. According to the information and explanations given to us, no undisputed amounts payable in respect of the above were in arrears as at March 31, 2017 for a period of more than six months from the date on when they become payable.
- b) According to the information and explanation given to us, there are no dues of income tax, sales tax, service tax, duty of customs, duty of excise, value added tax outstanding on account of any dispute.
- 8) In our opinion and according to the information and explanations given to us, the Company has not defaulted in the repayment of dues to banks. The Company has not taken any loan either from financial institutions or from the government and has not issued any debentures.
- 9) Based upon the audit procedures performed and the information and explanations given by the management, the company has not raised moneys by way of initial public offer or further public offer including debt instruments and term Loans. Accordingly, the provisions of clause 3 (ix) of the Order are not applicable to the Company and hence not commented upon.
- 10) Based upon the audit procedures performed and the information and explanations given by the management, we report that no fraud by the Company or on the company by its officers or employees has been noticed or reported during the year.
- 11) Based upon the audit procedures performed and the information and explanations given by the management, the managerial remuneration has been paid or provided in accordance with the requisite approvals mandated by the provisions of section 197 read with Schedule V to the Companies Act;
- 12) In our opinion, the Company is not a Nidhi Company. Therefore, the provisions of clause 4 (xii) of the Order are not applicable to the Company.
- 13) In our opinion, all transactions with the related parties are in compliance with section 177 and 188 of Companies Act, 2013 and the details have been disclosed in the Financial Statements as required by the applicable accounting standards.
- 14) Based upon the audit procedures performed and the information and explanations given by the management, the company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year under review. Accordingly, the provisions of clause 3 (xiv) of the Order are not applicable to the Company and hence not commented upon.



- 15) Based upon the audit procedures performed and the information and explanations given by the management, the company has not entered into any non-cash transactions with directors or persons connected with him. Accordingly, the provisions of clause 3 (xv) of the Order are not applicable to the Company and hence not commented upon.
- 16) In our opinion, the company is not required to be registered under section 45 IA of the Reserve Bank of India Act, 1934 and accordingly, the provisions of clause 3 (xvi) of the Order are not applicable to the Company and hence not commented upon.

for JOSHI VISHAL & ASSOCIATES
CHARTERED ACCOUNTANTS

PLACE: CHANDIGARH

DATE: 27-08-2017



(VISHAL JOSHI)
M.NO. 097336
FRN :016437N

**“Annexure B” to the Independent Auditor’s Report of even date on the Standalone
Financial Statements of Biodeal Pharmaceuticals Private Limited**

**Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143
of the Companies Act, 2013 (“theAct”)**

We have audited the internal financial controls over financial reporting of Biodeal Pharmaceuticals Private Limited (“the Company”) as of March 31, 2017 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management’s Responsibility for Internal Financial Controls

The Company’s management is responsible for establishing and maintaining internal financial controls. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors’ Responsibility

Our responsibility is to express an opinion on the Company’s internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls system over financial reporting.



Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2017, "the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India".

PLACE: CHANDIGARH

DATE: 27-08-2017

for **JOSHI VISHAL & ASSOCIATES**
CHARTERED ACCOUNTANTS



(VISHAL JOSHI)
M.NO. 097336
FRN :016437N

BIODEAL PHARMACEUTICALS PVT. LTD.
BALANCE SHEET AS AT 31ST MARCH, 2017

PARTICULARS	NOTE NO.	AS AT 31ST MARCH 2017	AS AT 31ST MARCH 2016
EQUITY AND LIABILITIES			
SHAREHOLDERS'S FUNDS			
SHARE CAPITAL	1	250000000	250000000
RESERVES AND SURPLUS	2	(3298342)	(12970768)
NON-CURRENT LIABILITIES			
LONG-TERM BORROWINGS	3	108799266	103056082
CURRENT LIABILITIES			
SHORT TERM BORROWINGS	4	68877804	56161671
TRADE PAYABLES	5	38016478	30293616
OTHER CURRENT LIABILITIES	6	14056539	17897375
TOTAL		476451744	444437976
ASSETS			
NON- CURRENT ASSETS			
FIXED ASSETS			
TANGIBLE ASSETS			
INTANGIBLE ASSET	7	266093260	251046602
NON- CURRENT INVESTMENT	8	10198175	6243714
DEFERRED TAX ASSET (NET)	9	50000	50000
		41741759	46074586
CURRENT ASSETS			
INVENTORIES	10	73776700	70202807
TRADE RECEIVABLES	11	54596782	56130688
CASH AND CASH EQUIVALENTS	12	7359756	4485048
SHORT TERM LOANS AND ADVANCES	13	22345749	9664076
OTHER CURRENTS ASSETS	14	289564	540455
TOTAL		476451744	444437976

AUDITORS REPORT

As per our separate report of even date annexed.

FOR JOSHI VISHAL & ASSOCIATES
CHARTERED ACCOUNTANTS



(VISHAL JOSHI)

PLACE : CHANDIGARH

DATE : 21-08-2017

Gurjankumar

DIRECTOR

Gurjankumar

DIN: 05203788

Subodh

DIRECTOR

Subodh Prasad Singh

DIN : 07148323

BIODEAL PHARMACEUTICALS PVT. LTD.
STATEMENT OF PROFIT AND LOSS AS ON 31ST MARCH, 2017

PARTICULARS	NOTE NO.	AS AT 31ST MARCH 2017	AS AT 31ST MARCH 2016
INCOME			
REVENUE FROM OPERATIONS	15	292468363	216176675
OTHER INCOME	16	3137219	490236
TOTAL REVENUE		295605582	216666911
EXPENSES:			
COST OF MATERIALS CONSUMED	17	129742203	82548596
CHANGE IN INVENTORIES OF FINISHED GOODS	18	2888772	5875580
STOCK-IN-PROCESS AND STOCK IN TRADE			
EMPLOYEE BENEFITS EXPENSE	19	67936755	51792998
FINANCE COSTS	20	18775789	15627363
DEPRECIATION AND AMORTISATION EXPENSES	21	18220312	15196847
OTHER EXPENSES	22	44036497	30541107
TOTAL EXPENSES		281600329	201582491
PROFIT/(LOSS) BEFORE TAX		14005253	15084420
TAX EXPENSES:			
CURRENT TAX		0	0
DEFERRED TAX		4332827	314244
PROFIT/(LOSS) FOR THE PERIOD		9672426	14770176
:EARNING PER EQUITY SHARE:-			
BASIC		0.39	0.59
DILUTED		0.39	0.59

AUDITORS REPORT

As per our separate report of even date annexed.

FOR JOSHI VISHAL & ASSOCIATES
CHARTERED ACCOUNTANTS



(VISHAL JOSHI)

PLACE : CHANDIGARH

DATE : 21-03-2017

Gunjan Kumar *Subodh Brasad Singh*
DIRECTOR DIRECTOR

Gunjan Kumar Subodh Brasad Singh

DIN: 05203788 DIN: 07148323

BIODEAL PHARMACEUTICALS PVT. LTD.
CASH FLOW STATEMENT

A CASH FLOW FROM OPERATING ACTIVITIES	As at 31st March, 2017	As at 31st March, 2016
Net Profit Before Tax	14005253	15084420
Adjustments for:		
Depreciation	18203468	15180004
Preliminary Expenses w/off	0	0
Deferred Revenue Expenditure	0	0
(Profit)/loss on sale of Assets	0	0
Interest & Finance Charges	18775789	15627363
Interest On Income Tax Refund	0	0
Interest on FD	0	0
Dividend Income	0	0
Operating Profit before Working Capital Changes	36979258	30807367
Adjustments for:	50984511	45891787
Decrease/(Increase) in Preliminary Expenses	0	0
Decrease/(Increase) in Receivables	(10896876)	(35380760)
Decrease/(Increase) in Inventories	(3573893)	(11609978)
Increase/(Decrease) in Payables	16598159	32046260
Cash generated from operations	53111900	30947309
Income Tax Adjustment	0	0
Interest On Income Tax Refund	0	0
Net Cash flow from Operating activities	53111900	30947309
B CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	(37884587)	(18806118)
Investment In Shares	0	0
Sale of Fixed Assets	680000	58593
Increase in Advances & others	0	0
Interest on FD	0	0
Dividend Income	0	0
Net Cash used in Investing activities	(37204587)	(18747525)
C CASH FLOW FROM FINANCING ACTIVITIES		
Increase/(Decrease) in Capital	0	0
Increase/(Decrease) in Share Application Money	0	0
Proceeds from Long term Borrowings	5743184	3056082
Interest paid	(18775789)	(15627363)
Net Cash used in financing activities	(13032606)	(12571281)
Net increase/(Decrease) in cash & Cash Equivalents	2874708	(371497)
Opening Balance	4485048	4856545
Balance at close	7359756	4485048
Cash & Cash Equivalents	As on 31/03/2017	As on 31/03/2016
Cash in Hand	822616	297081
Cash at Bank	6537140	4187967
Cash & Cash equivalents as stated	7359756	4485048

AUDITORS REPORT

As per our separate report of even date annexed.

FOR JOSHI VISHAL & ASSOCIATES

CHARTERED ACCOUNTANTS



DATE : 21-08-2017
PLACE : CHANDIGARH

Gurpreet Kumar

DIRECTOR

Gurpreet Kumar

DIN: 05203788

Subath Brasad Singh

DIRECTOR

Subath Brasad Singh

DIN: 07148323

BIODEAL PHARMACEUTICALS PVT. LTD.

I. SHARE CAPITAL

PARTICULARS	AS AT 31ST	
	MARCH 2017	MARCH 2016
AUTHORISED SHARE CAPITAL		
25000000 EQUITY SHARES OF RS 10/- EACH	250000000	250000000
TOTAL	250000000	250000000
ISSUED SUBSCRIBED AND PAID UP		
25000000 (PREVIOUS YEAR 25000000) EQUITY SHARES OF RS. 10/- EACH FULLY PAID UP	250000000	250000000
TOTAL	250000000	250000000

1A. RECONCILIATION OF THE SHARES OUTSTANDING AT THE BEGINNING AND AT THE END OF THE REPORTING PERIOD

PARTICULARS	AS AT 31ST		AS AT 31ST	
	MARCH 2017		MARCH 2016	
	NO. OF SHARES	AMOUNT	NO. OF SHARES	AMOUNT
EQUITY SHARES				
AT THE BEGINNING OF THE YEAR	25000000	250000000	25000000	250000000
ADD:-SHARES ISSUED DURING THE YEAR.	0	0	0	0
BALANCE AS AT THE END OF YEAR	25000000	250000000	25000000	250000000

1B. DETAILS OF SHARES HELD BY THE SHAREHOLDERS HOLDING MORE THAN 5% OF THE AGGREGATE SHARES IN THE COMPANY

NAME OF SHAREHOLDER	NO. OF SHARES		%	
	SHARES	HOLDING	SHARES	HOLDING
NITIN P. PATEL	0	0	1271900	5.09
POPATLAL N. PATEL	0	0	1449152	5.80
CHANDRAKANT P. PATEL	0	0	1271895	5.09
DEEPAK P. PATEL	0	0	1271895	5.09
ANURAG KUMAR	24991700	99.97	12750000	51.00

1C. RIGHTS, PREFERENCES AND RESTRICTIONS ATTACHED TO SHARES

EQUITY SHARES:- THE COMPANY HAS ONE CLASS OF EQUITY SHARES HAVING PAR VALUE OF RS. 10 PER SHARE. EACH SHAREHOLDER IS ELIGIBLE FOR VOTE AS PER THEIR SHAREHOLDING.

Grunjan Kumar
DIRECTOR

Grunjan Kumar
DIN: 05203788

Subodh
DIRECTOR

Subodh Braasad Singh
DIN: 07148323



BIODEAL PHARMACEUTICALS PVT. LTD.

2. RESERVES AND SURPLUS

<u>PARTICULARS</u>	<u>AS AT 31ST</u> <u>MARCH 2017</u>	<u>AS AT 31ST</u> <u>MARCH 2016</u>
<u>GENERAL RESERVE</u>		
AS PER LAST BALANCE SHEET	(12970768)	(106716209)
ADD/LESS:- DEFFERED TAX LIABILITY/ASSET	0	78975265
ADD:- TRANSFERRED FROM PROFIT AND LOSS ACCOUNT	9672426	14770176
	<u>(3298342)</u>	<u>(12970768)</u>
<u>PROFIT AND LOSS ACCOUNT</u>		
AS PER LAST BALANCE SHEET	0	0
ADD:- PROFIT (LOSS)FOR THE YEAR	9672426	14770176
	<u>9672426</u>	<u>14770176</u>
LESS:- APPROPRIATIONS TRANSFERRED TO GENERAL RESERVE	9672426	14770176
	<u>0</u>	<u>0</u>
TOTAL	<u><u>(3298342)</u></u>	<u><u>(12970768)</u></u>

Gunjan Kumar

DIRECTOR

Gunjan Kumar
DIN: 05203788

Subodh

DIRECTOR

Subodh Beasad Singh
DIN: 07148323



BIODEAL PHARMACEUTICALS PVT. LTD.

3. LONG TERM BORROWINGS

PARTICULARS	AS AT 31ST MARCH 2017		AS AT 31ST MARCH 2016	
	NON CURRENT	CURRENT	NON CURRENT	CURRENT
SECURED				
AXIS BANK BUS LOAN	696862	259930	956792	233631
AXIS BANK ECCO LOAN	156231	58555	214786	52637
AXIS BANK ERTIGA LOAN	394141	142534	536675	128387
AXIS BANK VERNA LOAN	546099	165592	711691	149673
AXIS BANK ERTIGA 2 LOAN	499577	136561	636138	123862
AXIS BANK BOLERO LOAN	480418	104712	0	0
CANARA BANK TERM LOAN	17860750	3750000	0	0
	20634078	4617884	3056082	688190
UNSECURED LOANS				
	88165188	0	100000000	9000000
	88165188	0	100000000	9000000
TOTAL	108799266	4617884	103056082	9688190

4. SHORT TERM BORROWINGS

PARTICULARS	AS AT 31ST MARCH 2017		AS AT 31ST MARCH 2016	
	SECURED			
CANARA BANK -CASH CREDIT A/C		68877804		56161671
TOTAL		68877804		56161671

(WORKING CAPITAL LOAN FROM BANK IS SECURED BY HYPOTHECATION OF STOCK OF RAW MATERIAL, STOCK IN PROCESS, FINISH GOODS AND RECEIVABLE)

Gunjan Kumar
DIRECTOR
Gunjan Kumar
DIN; 05203788

Shugh
DIRECTOR
Subodh Prasad Singh
DIN: 07148323



BIODEAL PHARMACEUTICALS PVT. LTD.

5. TRADE PAYABLES

<u>PARTICULARS</u>	<u>AS AT 31ST MARCH 2017</u>	<u>AS AT 31ST MARCH 2016</u>
OTHERS(CREDITORS EXCLUDING FIXED ASSETS)	38016478	30293616
TOTAL	<u>38016478</u>	<u>30293616</u>

6. OTHER CURRENT LIABILITIES

<u>PARTICULARS</u>	<u>AS AT 31ST MARCH 2017</u>	<u>AS AT 31ST MARCH 2016</u>
CURRENT MATURITIES OF LONG TERM DEBT (REFER NOTE 3)	4617884	9688190
ADVANCES FROM CUSTOMERS	2292914	1371277
OTHERS PAYABLES	7145741	6837908
TOTAL	<u>14056539</u>	<u>17897375</u>

Gunjan Kumar
DIRECTOR

Gunjan Kumar
DIN: 05203788

Subodh Prasad Singh
DIRECTOR

Subodh Prasad Singh
DIN: 07148323



BIODEAL PHARMACEUTICALS PVT. LTD.

Notes to Balance Sheet as at March 31, 2017
Note 7:- Fixed Assets

Figures in (Rs.)

Tangible assets	GROSS				DEPRECIATION/AMORTISATION				NET	
	Opening Balance	Additions	Deductions s/Trf	Total	Up to the end of the previous year	During the year	Written back	Total as at the year end	Current year	Previous year
Land	42599000	0	0	42599000	0	0	0	0	42599000	42599000
Building	43708942	5483350	0	49192292	8631533	1385599	0	10017132	39175160	35077409
Electrical Installation	6023891	167885	0	6191776	2427957	277604	0	2705562	3486214	3595934
Computer	3771464	801242	0	4572706	3060547	583178	0	3643725	928981	710917
Plant & Machinery	250595223	23972263	680000	273887486	98381643	12563919	0	110945561	162941925	152213581
Misc. Fixed Assets	16234913	1053351	0	17288264	5666939	812083	0	6479022	10809242	10567974
Vehicle	6720890	689976	0	7410866	2385427	607903	0	2993330	4417536	4335463
Furniture & Fixture	6084043	551846	0	6635889	4137717	762970	0	4900687	1735202	1946326
Total (A)	375738366	32719913	680000	407778279	124691764	16992355	0	141685019	266093260	251046602
Intangible assets										
Product Registration	6937460	5164674	0	12102134	693746	1210213	0	1903959	10198175	6243714
Total (B)	6937460	5164674	0	12102134	693746	1210213	0	1903959	10198175	6243714
Total (A)+(B)	382675826	37884587	680000	419880413	125385510	18203468	0	143588978	276291435	257290316
Previous Year	363928301	18806118	58593	382675826	110205506	15180004	0	124691764	257290316	253722795




 DIRECTOR
 Gunjan Kumar
 DN: 05803788


 DIRECTOR
 Subodh Prasad Singh
 DN: 07148323

BIODEAL PHARMACEUTICALS PVT. LTD.

8. NON-CURRENT INVESTMENT

PARTICULARS	AS AT 31ST MARCH 2017	AS AT 31ST MARCH 2016
INVESTMENT IN SHIVALIK SOLID WASTE MANAGEMENT LTD.	50000	50000
	<u>50000</u>	<u>50000</u>

9. DEFERRED TAX ASSET (NET)

PARTICULARS	AS AT 31ST MARCH 2017	AS AT 31ST MARCH 2016
DEFERRED TAX ASSET RELATED TO LOSSES	41741759	46074586
TOTAL	<u>41741759</u>	<u>46074586</u>

10. INVENTORIES

PARTICULARS	AS AT 31ST MARCH 2017	AS AT 31ST MARCH 2016
RAW MATERIAL	27629216	26023088
PACKING MATERIAL	34783074	34252505
CONSUMABLE STORE	8577926	4251958
FINISHED GOODS	2786484	5675256
TOTAL	<u>73776700</u>	<u>70202807</u>

11. TRADE RECEIVABLES

UNSECURED AND CONSIDERED GOOD

PARTICULARS	AS AT 31ST MARCH 2017	AS AT 31ST MARCH 2016
OVER SIX MONTHS	95206	1169398
OTHERS	54501576	54961290
TOTAL	<u>54596782</u>	<u>56130688</u>



Gunjan Kumar
DIRECTOR
Gunjan Kumar
DIN: 0520 3788

Subodh Prasad Singh
DIRECTOR
Subodh Prasad Singh
DIN: 07148323

BIODEAL PHARMACEUTICALS PVT. LTD.

12. CASH AND CASH EQUIVALENTS

PARTICULARS	AS AT 31ST MARCH 2017	AS AT 31ST MARCH 2016
BALANCE WITH BANKS	6537140	4187967
CASH IN HAND	822616	297081
TOTAL	7359756	4485048

13. SHORT TERM LOANS AND ADVANCES

PARTICULARS	AS AT 31ST MARCH 2017	AS AT 31ST MARCH 2016
BALANCE WITH CUSTOMS, EXCISE ,TDS,SALES TAX ETC.	7231280	7025573
OTHERS (ADVANCES TO SUPPLIERS)	13555309	1808823
STAFF ADVANCE	738940	56642
PREPAID EXPENSES	820220	773038
TOTAL	22345749	9664076

14. OTHER CURRENT ASSETS

PARTICULARS	AS AT 31ST MARCH 2017	AS AT 31ST MARCH 2016
UNAMORTISED PRELIMINARY EXPENSES	0	16844
SECURITIES	289564	284338
INSURANCE CLAIM RECEIVABLE	0	239273
TOTAL	289564	540455

Gurpreet Kumar
DIRECTOR

Gurpreet Kumar
DIN: 05803788

Subodh Bhasad Singh
DIRECTOR

Subodh Bhasad Singh
DIN: 07148323



BIODEAL PHARMACEUTICALS PVT. LTD.

15. REVENUE FROM OPERATIONS

<u>PARTICULARS</u>	<u>AS AT 31ST MARCH, 2017</u>	<u>AS AT 31ST MARCH, 2016</u>
SALE OF PRODUCTS	193287757	169028179
JOB WORK	99180606	47148496
TOTAL	<u>292468363</u>	<u>216176675</u>

16. OTHER INCOME

<u>PARTICULARS</u>	<u>AS AT 31ST MARCH, 2017</u>	<u>AS AT 31ST MARCH, 2016</u>
OTHER INCOME	3137219	490236
TOTAL	<u>3137219</u>	<u>490236</u>

Grunjan Kumar
DIRECTOR

Grunjan Kumar
DIN: 05203788

Subodh
DIRECTOR

Subodh Brahad Singh
DIN: 07148323



BIODEAL PHARMACEUTICALS PVT. LTD.

17. COST OF MATERIAL CONSUMED

PARTICULARS	AS AT 31ST MARCH, 2017	AS AT 31ST MARCH,2016
RAW MATERIAL CONSUMED	43427259	29402640
CONSUMABLE STORE	7866135	8236773
PACKING MATERIAL	78448809	44909183
TOTAL	129742203	82548596

18. CHANGES IN INVENTORIES OF FINISHED GOODS, STOCK-IN-PROCESS AND STOCK-IN-TRADE

PARTICULARS	AS AT 31ST MARCH, 2017	AS AT 31ST MARCH,2016
<u>INVENTORIES (AT CLOSE)</u>		
FINISHED GOODS/STOCK IN TRADE	2786484	5675256
<u>INVENTORIES (AT COMMENCEMENT)</u>		
FINISHED GOODS/STOCK IN TRADE	5675256	11550836
TOTAL	2888772	5875580

19. EMPLOYEE BENEFITS EXPENSES

PARTICULARS	AS AT 31ST MARCH, 2017	AS AT 31ST MARCH,2016
SALARIES AND WAGES	62153107	48232641
CONTRIBUTIONS TO PROVIDENT AND OTHER FUNDS	2723553	2071568
STAFF WELFARE EXPENSES	3060095	1488789
TOTAL	67936755	51792998

Gurjant Kumar
DIRECTOR

Gurjant Kumar
DIN: 05203788

Subal Singh
DIRECTOR

Subal Singh
DIN: 0748323



BIODEAL PHARMACEUTICALS PVT. LTD.

20. FINANCE COSTS

PARTICULARS	AS AT 31ST MARCH, 2017	AS AT 31ST MARCH, 2016
INTEREST EXPENSES (BANK CHARGES)	8992678	5627363
INTEREST ON UNSECURED LOAN	9783111	10000000
TOTAL	18775789	15627363

21. DEPRECIATION AND AMORTISATION EXPENSES

PARTICULARS	AS AT 31ST MARCH, 2017	AS AT 31ST MARCH, 2016
DEPRECIATION ON FIXED ASSETS	16993255	14486258
AMORTISATION OF PRELIMINARY EXPENSES	16844	16844
PRODUCT REGISTRATION CHARGES WRITTEN OFF	1210213	693746
TOTAL	18220312	15196847

Grunjan Kumar
DIRECTOR

Grunjan Kumar
DIN: 05203788

Subodh Prasad Singh
DIRECTOR

Subodh Prasad Singh
DIN: 07148323



BIODEAL PHARMACEUTICALS PVT. LTD.

22. OTHER EXPENSES

PARTICULARS	AS AT 31ST MARCH, 2017	AS AT 31ST MARCH, 2016
ADVERTISEMENT	5000	57834
AUDITOR'S REMUNERATION	80150	80150
CLEANING & SANITATION	125189	165237
CLEARING AND FORWADING	1875567	2368538
CONSULTANCY EXPENSES	391575	234265
DIWALI GIFTS	405610	211430
ELECTRICITY & WATER CHARGES	13413601	9387401
FEES & TAXES	396755	136351
FREIGHT INWARD	853594	686001
FREIGHT OUTWARD	778739	1199291
GENSET EXPENSES	8951132	6039510
INSURANCE	716825	637970
INTERNET EXPENSES	425382	333402
MEMBERSHIP & SUBSCRIPTION	57150	47672
OFFICE EXPENSES	98646	76569
POSTAGE & TELEGRAM	99769	41604
PRINTING & STATIONARY	381015	324308
REST HOUSE EXPENSES	449104	31533
REPAIRS & MAINTENANCE		
- MACHINERY	2126015	1448991
- OTHER	566241	1076148
BUSINESS PROMOTION	1317025	62250
SECURITY EXPENSES	1332912	1206718
PRODUCTION INCENTIVE	2529456	0
SALES COMMISSION	55290	0
TELEPHONES	144412	97965
TESTING EXPENSES	2567300	1760356
TRAVELLING & CONVEYANCE-DIRECTOR'S	1293431	90393
TRAVELLING & CONVEYANCE-OTHERS	1150740	1212186
VEHICLE REPAIR & MAINTENANCE	1648238	1030360
NET (GAIN)/LOSS ON FOREIGN CURRENCY TRANSACTION	(199364)	496674
TOTAL	44036497	30541107



Chandigarh X

Chugh

BIODEAL PHARMACEUTICALS PRIVATE LIMITED
VILLAGE SAINI MAJRA, NALAGARH ROPAR ROAD, TEHSIL NALAGARH,
DISTT. SOLAN, HIMACHAL PRADESH

SIGNIFICANT ACCOUNTING POLICIES AND NOTES TO ACCOUNTS

D) SIGNIFICANT ACCOUNTING POLICIES:-

1 Basis of Preparation of Financial Statements:-

The company maintains its accounts on accrual basis following the historical cost conventions in accordance with generally accepted Accounting principles (GAAP) and in compliance with the Accounting Standards referred to in section 133 and other requirements of the Companies Act 2013.

The preparation of the financial statements in conformity with GAAP requires that the management of the company makes estimates and assumptions that affect the reported amounts of profits and losses of the period, the reported balances of assets and liabilities and the disclosures relating to contingent liabilities as of the date of the financial statements.

2 Fixed Assets:-

Fixed Assets are stated at cost, less accumulated depreciation and impairment losses if any. All cost related to the acquisition and installation of Fixed Assets are capitalised.

Borrowing costs that are attributable to the acquisition or construction of qualifying assets are capitalised as part of the cost of such assets. A qualifying asset is one that necessarily takes substantial period of time to get ready for intended use.

3 Depreciation:-

Depreciation on fixed assets is provided on written down method basis in accordance with & in the manner as specified in the Schedule II to the Companies Act, 2013."

4 Inventories:-

Inventories are valued at lower of cost and net realisable value.

5 Revenue Recognition:-

Revenue is recognized based on the nature of activity when consideration can be reasonably measured and there exists reasonable certainty of its recovery.

- a. Revenue from sale of goods is recognized when the substantial risks and rewards of ownership are transferred to the buyer under the terms of the contract.
- b. Other income is accounted for on accrual basis as and when the right to receive arises.

6 Research and Development:-

Revenue expenditure incurred on Research & Development is charged to Profit & Loss Account in the year in which it is incurred.

7 Investments:-

- i Investments are classified as Long Term and Current Investments.
- ii Long Term Investments are carried at Cost. Provision for Diminution; if any in the value of each long term investment is made to recognize a decline other than of temporary nature.
- iii Current Investments are stated at lower of cost or fair value and the lower of cost or fair value and resultant decline, if any, is charged to revenue.
- iv Dividend income is recognized when the right to receive payment is established.



Arjun Kumar x *Singh*

8 Retirement Benefits:-

The company's contribution to defined contribution plans is charged to Profit & Loss Account as incurred. Defined Contribution Plan is provided on the basis of valuation as at Balance Sheet date based on an actuarial valuation.

9 Taxes on Income:

Tax expenses comprises of current and deferred income tax, fringe benefit tax and wealth tax. Current income tax and fringe benefits tax is measured at the amount expected to be paid to the tax authorities in accordance with the Indian Income Tax Act. Deferred income taxes reflects the impact of current year timing differences between taxable income and accounting income for the year and reversal of timing differences of earlier years.

Deferred tax is measured based on the tax rates and the tax laws enacted or substantively enacted at the balance sheet date. Deferred tax assets are recognized only to the extent that there is reasonable certainty that sufficient further taxable income will be available against which such deferred tax assets can be realized. If the company has carry forward of unabsorbed depreciation and tax losses, deferred tax, assets are recognized only if there is virtual certainty that such deferred tax assets can be realized against further taxable profits. Unrecognized deferred tax assets of earlier years are re-assessed and recognized to the extent that it has become reasonably certain that further taxable income will be available against which such deferred tax assets can be realized.

10 Impairment of Assets:-

At each balance sheet date, the carrying amounts of fixed assets are reviewed by the management to determine whether there is any indication that those assets suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of impairment loss (recoverable amount is the higher of an assets net selling price or value in use). In assessing the value in use, the estimated future cash flows expected from the continuing use of the assets and from its disposal are discounted to their present value using a pre discounted rate that reflects the current market assessment of time value of money and risks specific to the asset.

Reversal of impairment loss is recognized immediately as income in the profit and Loss account.

11 Provisions, Contingent Liabilities and Contingent Assets

A provision is recognized when an enterprise has

- 1 A present obligation as a result of past events.
- 2 It is probable that an outflow of resources will be required to settle the obligation.
- 3 In respect of which a reliable estimate can be made.

Provisions are determined based on the best estimates required to fulfill the obligation on the balance sheet date. Provisions are reviewed at each balance sheet date and adjusted to reflect the current best estimates.

12 Earnings per Share

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders (after deducting preference dividend & taxes) by the weighted average number of equity shares outstanding during the year. Equity shares that are partly paid up are treated as a fraction of an equity share to the extent they entitled to participate in dividends. The weighted average numbers of equity shares outstanding during the year are adjusted for events such as bonus issue, bonus element in a right issue to the existing shareholders, share split and consolidation of shares.

For the purpose of calculating diluted EPS, the net profit or loss attributable to equity share holders and weighted average number of equity shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

Chandrasekhar x *Chugh*



13 **Cash and Cash equivalents**

Cash and cash equivalent in the balance sheet comprises cash at bank, cash in hand & short term investments

14 **Foreign Exchange Transactions**

Foreign Exchange Transactions are recorded at the exchange rate prevailing on the date of transaction. All exchange differences in respect of foreign currency transactions are dealt with in the Profit & Loss Account.



Sanjay Kumar x *Singh*

II) NOTES TO ACCOUNTS

- 1 Land of the Company is yet to be entered in Revenue Records of the Himachal State Revenue Authorities.
- 2 The balances of advances, debtors & creditors are subject to confirmation.
- 3 In the opinion of the Management, the current assets, loans and advances, if realized in the ordinary course of business, have a realizable value which is at least equal to the value at which these are stated in the accounts.
- 4 The amount of Service Tax payable was paid before the due date of filing of Service Tax Return for the year.
- 5 Contingent Liability: NIL
- 6 The liability in respect of Sales Tax and Income Tax has been accounted for on the basis of respective returns filed

7 AUDITORS REMUNERATION

Audit Fee	Current Year	Previous Year
	80150/-	80150/-

8 **Earning Per Share**

	2016-17	2015-16
a. Weighted average number of shares	25000000	25000000
b. Net profit/(loss) available for Equity Share Holders	9672426	14770176
c. Basic & Diluted Earning per Share	0.39	0.58

9 **Related Party Disclosure**

Disclosure as required by the Accounting Standard 18: Related Party Disclosures issued by the Related parties

A. Related parties

1 Key Management Personnel

Sh. Gunjan Kumar
Sh. Subodh Singh Prasad

2 Associated Companies, Firms and Relatives

Sh. Chandrakant P. Patel
Sh. Deepak Bhai P. Patel
Sh. Popet Bhai N. Patel
Devang Pharma Pvt. Ltd
Devang Paper Mills Pvt. Ltd
Marshal Leasing & Finance Co.
Lobster Overseas
Atlantas Worldwide Pvt. Ltd.



Gunjan Kumar x Singh

B. Transactions with Related Parties

	(In Laes)	(In Laes)
	Current Year	Previous Year
Remuneration to Directors and their Relatives	0.00	9.00
Interest to Directors and their Relatives	97.83	100.00
Purchases from associate companies & Firms	0.00	0.00
Sales to Holding Company	0.00	0.00
Sales to associate companies & Firms	87.43	0.00
Rendering of Services from associate companies, Firms &	31.30	0.00
Rendering of Services to associate companies, Firms & relatives	0.00	0.00

10 **Deferred Tax Liability:**

The deferred tax liability as on 31.03.17 amounting to Rs.4332827/- has been charged to profit account. Deferred tax assets and liabilities are being offset as they relate to taxes income levied by the same governing taxation laws. Major components of deferred tax liability are as under:

Particulars	As on 31.03.17	As on 31.03.16
Deferred Tax Liability		
Difference between carrying amount of Fixed Assets	4.37	10.17
Total A	4.37	10.17
Deferred Tax Assets		
Unabsorbed Depreciation as per Returns	21.00	0.00
Business Loss Absorbed in Current Year	123.6	
Sales Tax	-	-
Penalty	-	-
Donation	-	-
Gratuity	-	-
Total B	144.60	-
Net Timing Difference (A-B)	(140.23)	10.17
Net Deferred Tax Liability	43.33	3.14

11 The debit and credit balance in the accounts of Debtors and Suppliers are subject to their respective confirmation and reconciliation.

12 In the opinion of the Board of Directors, the current assets, loans and advances are having the value as stated in the balance sheet, if realized in the ordinary course of business.

13 **Impairment of Assets**

As per AS-28 Impairment of Assets issued by ICAI, the management has reviewed its cash generating unit as on 31.03.2017. No such indication has been found by the management that the recoverable amount of Asset is less than the carrying amount. Hence no impairment loss on asset has been recognized.

Arjun Kumar

x

Arjun



14 Note on Demonetisation

Details of Specified Bank Notes (SBN) held and transacted during the period from 8th November, 2016 to 30th December 2016 as provided in the Table below:

Particulars	SBNs	Other Denomination Notes	Amount in (Rs.)
Closing Cash in Hand as on November 8, 2016	22000	700292	722292
(+) Permitted Receipts	-	424000	424000
(-) Permitted Payments	6000	52563	58563
(-) Amount deposited in Banks	16000	-	16000
Closing Cash in Hand as on December 30, 2016	-	1021729	1071729

15 There was no employee employed through out the year or for a part of the year who was getting salary in excess of the limits specified under Section 134 of the Companies Act 2013.

16 The figures relating to the previous year have been regrouped / rearranged wherever necessary to make them comparable with the current year.

Place: Chandigarh.

Date : 21-08-2017

For Joshi Vishal & Associates
Chartered Accountants



Proprietor
M.No 097336

Amrinder Kumar

X

Bhugh